Quality assurance of surgery in the randomized ST03 trial of perioperative chemotherapy in carcinoma of the stomach and gastro-oesophageal junction

W H Allum, E C Smyth, J M Blazeby, H I Grabsch, S M Griffin, S Rowley, F H Cafferty, R E Langley, D Cunningham, W H Allum, E C Smyth, J M Blazeby, H I Grabsch, S M Griffin, S Rowley, F H Cafferty, R E Langley, D Cunningham

Abstract

Background: The UK Medical Research Council ST03 trial compared perioperative epirubicin, cisplatin and capecitabine (ECX) chemotherapy with or without bevacizumab (B) in gastric and oesophagogastric junctional cancer. No difference in survival was noted between the arms of the trial. The present study reviewed the standards and performance of surgery in the context of the protocol-specified surgical criteria.

Methods: Surgical and pathological clinical report forms were reviewed to determine adherence to the surgical protocols, perioperative morbidity and mortality, and final histopathological stage for all patients treated in the study.

Results: Of 1063 patients randomized, 895 (84·2 per cent) underwent resection; surgical details were available for 880 (98·3 per cent). Postoperative assessment data were available for 873 patients; complications occurred in 458 (52·5 per cent) overall, of whom 71 (8·1 per cent) developed complications deemed to be life-threatening by the responsible clinician. The most common complications were respiratory (211 patients, 24·2 per cent). The anastomotic leak rate was 118 of 873 (13·5 per cent) overall; among those who underwent oesophagogastrectomy, the rate was higher in the group receiving ECX-B (23·6 per cent versus 9·9 per cent in the ECX group). Pathological assessment data were available for 845 patients. At least 15 nodes were removed in 82·5 per cent of resections and the median lymph node harvest was 24 (i.q.r. 17-34). Twenty-five or more nodes were removed in 49·0 per cent of patients. Histopathologically, the R1 rate was 24·9 per cent (208 of 834 patients). An R1 resection was more common for proximal tumours.

Conclusion: In the ST03 trial, the performance of surgery met the protocol-stipulated criteria. Registration number: NCT00450203 ( http://www.clinicaltrials.gov).

© 2019 The Authors. BJS published by John Wiley & Sons Ltd on behalf of BJS Society Ltd.

Figures

Figure 1
Figure 1
Flow diagram for ST03 trialECX, epirubicin, cisplatin and capecitabine; B, bevacizumab.

References

    1. Japanese Gastric Cancer Association . Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer 2017; 20: 1–19.
    1. Cuschieri A, Weeden S, Fielding J, Bancewicz J, Craven J, Joypaul V et al Patient survival after D1 and D2 resections for gastric cancer: long‐term results of the MRC randomized surgical trial. Surgical Co‐operative Group. Br J Cancer 1999; 79: 1522–1530.
    1. Bonenkamp JJ, Songun I, Hermans J, Sasako M, Welvaart K, Plukker JT et al Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet 1995; 345: 745–748.
    1. Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15‐year follow‐up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 2010; 11: 439–449.
    1. Rüdiger Siewert J, Feith M, Werner M, Stein HJ. Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1002 consecutive patients. Ann Surg 2000; 232: 353–361.
    1. Lerut T, Nafteux P, Moons J, Coosemans W, Decker G, De Leyn P et al Three‐field lymphadenectomy for carcinoma of the esophagus and gastroesophageal junction in 174 R0 resections: impact on staging, disease‐free survival, and outcome: a plea for adaptation of TNM classification in upper‐half esophageal carcinoma. Ann Surg 2004; 240: 962–974.
    1. Griffin SM. Surgery for cancer of the oesophagus In A Companion to Specialist Surgical Training; Upper Gastrointestinal Surgery, Griffin SM, Raimes SA. (eds). WB Saunders: London, 1998; 111–144.
    1. Allum WH, Blazeby JM, Griffin SM, Cunningham D, Jankowski JA, Wong R; Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland, the British Society of Gastroenterology and the British Association of Surgical Oncology . Guidelines for the management of oesophageal and gastric cancer. Gut 2011; 60: 1449–1472.
    1. Moehler M, Al‐Batran SE, Andus T, Anthuber M, Arends J, Arnold D et al; AWMF. [German S3‐guideline ‘Diagnosis and treatment of esophagogastric cancer’.] Z Gastroenterol 2011; 49: 461–531.
    1. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M et al; MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11–20.
    1. Cunningham D, Stenning SP, Smyth EC, Okines AF, Allum WH, Rowley S et al Peri‐operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open‐label, randomised phase 2‐3 trial. Lancet Oncol 2017; 18: 357–370.
    1. AJCC . AJCC Cancer Staging Manual (7th edn). Springer International Publishing: New York, 2010.
    1. Sobin LH, Wittekind C. (eds). TNM Classification of Malignant Tumours (6th edn). John Wiley: New York, 2002.
    1. Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE. Long‐term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol 2009; 27: 5062–5067.
    1. MRC Clinical Trials Unit . ST03 Trial Protocol [accessed 13 February 2019].
    1. Bosman FT, Carneiro F, Hruban RH, Theise ND. (eds). WHO Classification of Tumours of the Digestive System (4th edn). IARC: Lyon, 2010.
    1. Mapstone NP. Standards and Datasets for Reporting Cancers – Dataset for the Histopathological Reporting of Oesophageal Carcinoma (2nd edn). Royal College of Pathologists: London, 2006.
    1. Novelli M. Standards and Datasets for Reporting Cancers –Dataset for the Histopathological Reporting of Gastric Carcinoma (2nd edn). Royal College of Pathologists: London, 2006.
    1. Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry‐Amar M, Petiot JF et al Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma: clinicopathologic correlations. Cancer 1994; 73: 2680–2686.
    1. National Cancer Institute, National Institutes of Health, US Department of Health and Human Services . Common Terminology Criteria for Adverse events (CTCAE). Version 3. National Cancer Institute, National Institutes of Health, US Department of Health and Human Services: Washington DC, 2003.
    1. Blencowe NS, Chana P, Whistance RN, Stevens D, Wong NA, Falk SJ et al Outcome reporting in neoadjuvant surgical trials: a systematic review of the literature and proposals for new standards. J Natl Cancer Inst 2014; 106: dju217.
    1. Claassen YHM, de Steur WO, Hartgrink HH, Dikken JL, van Sandick JW, van Grieken NCT et al Surgicopathological quality control and protocol adherence to lymphadenectomy in the CRITICS gastric cancer trial. Ann Surg 2018; 268: 1008–1013.
    1. Healthcare Quality Improvement Partnership . National Oesophago‐gastric Cancer Audit 2017. Healthcare Quality Improvement Partnership: London, 2017.
    1. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004; 240: 205–213.
    1. Low DE, Alderson D, Cecconello I, Chang AC, Darling GE, D'Journo XB et al International consensus on standardization of data collection for complications associated with esophagectomy: Esophagectomy Complications Consensus Group (ECCG). Ann Surg 2015; 262: 286–294.
    1. Baiocchi GL, Giacopuzzi S, Marrelli D, Reim D, Piessen G, Matos da Costa P et al International consensus on a complications list after gastrectomy for cancer. Gastric Cancer 2019; 22: 172–189.
    1. Alderson D, Cunningham D, Nankivell M, Blazeby JM, Griffin SM, Crellin A et al Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open‐label, randomised phase 3 trial. Lancet Oncol 2017; 18: 1249–1260.
    1. van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP et al; CROSS Group. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012; 366: 2074–2084.
    1. Al‐Batran SE, Homann N, Schmalenberg H, Kopp HG, Haag GM, Luley KB et al Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4‐AIO): a multicenter, randomized phase 3 trial. J Clin Oncol 2017; 35(Suppl): Abstract 4004.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj